The present disclosure relates to a novel bacteriophage having specific antibacterial activity against Cronobacter sakazakii and a method for preparing an encapsulated bacteriophage powder. The novel bacteriophage of the present disclosure exhibits high specificity for Cronobacter sakazakii, excellent lytic activity, rapid and sustained antimicrobial activity, and superior stability with respect to temperature and pH. In addition, according to the present disclosure, by encapsulating the bacteriophage using collagen peptide, the survivability of the bacteriophage can be improved. The encapsulated bacteriophage thus prepared remains stably viable even after being converted into powder form, maintains excellent antimicrobial activity, and offers enhanced convenience in distribution and use, thereby demonstrating high industrial applicability.

Provided is a bacteria-targeting capsid particle that is non-proliferative and has a high bactericidal effect. A capsid protein of a bacteriophage is prepared by a capsid nucleic acid element that synthesizes the capsid, which is divided from the bacteriophage genome and does not include a packaging region, but mainly includes the virion region. A bacteria-targeting capsid particle element (Bacteria-targeting capsid particle, B-CAP) is divided from a part of the bacteriophage genome other than the capsid nucleic acid element and includes a nucleic acid injection region, a replication region necessary for nucleic acid replication, and a packaging region. Although the assembled bacteria-targeting capsid particle (B-CAP) is non-proliferative, it can carry long DNA strands that give them new biological functions, such as bactericidal effects, or the other biological functions.

Provided is a bacteria-targeting capsid particle that is non-proliferative and has a high bactericidal effect. A capsid protein of a bacteriophage is prepared by a capsid nucleic acid element that synthesizes the capsid, which is divided from the bacteriophage genome and does not include a packaging region, but mainly includes the virion region. A bacteria-targeting capsid particle element (Bacteria-targeting capsid particle, B-CAP) is divided from a part of the bacteriophage genome other than the capsid nucleic acid element and includes a nucleic acid injection region, a replication region necessary for nucleic acid replication, and a packaging region. Although the assembled bacteria-targeting capsid particle (B-CAP) is non-proliferative, it can carry long DNA strands that give them new biological functions, such as bactericidal effects, or the other biological functions.

The present invention relates to solid, at least three-phase active substance preparations, in which two separate phases are embedded multiparticulately into a coherent, active substance-free and antioxidant-free phase, where one of the embedded phases comprises at least one oxidation-sensitive active substance and the second comprises at least one antioxidant. The invention also relates to a method for producing these active substance preparations, and to the use thereof in food supplements, foods, feeds, body care products, and pharmaceuticals.

The present invention relates to solid, at least three-phase active substance preparations, in which two separate phases are embedded multiparticulately into a coherent, active substance-free and antioxidant-free phase, where one of the embedded phases comprises at least one oxidation-sensitive active substance and the second comprises at least one antioxidant. The invention also relates to a method for producing these active substance preparations, and to the use thereof in food supplements, foods, feeds, body care products, and pharmaceuticals.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as Mirabilis jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as Mirabilis jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

A strainer basket system may include a reservoir in which a strainer basket is positioned and a chemical dispensing docking station. The chemical dispensing docking station may have a cavity that receives a container of chemical to be dispensed and a retention mechanism that is configured to mechanically engage and retain the container of chemical, when inserted into the cavity. The docking station may also include a piercing member positioned to pierce the container of chemical as the container of chemical is inserted into the cavity, thereby releasing chemical into the reservoir and/or strainer basket.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.